meglumine antimoniate has been researched along with Splenic Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buffet, PA; Derouin, F; Garin, YJ; Nassar, N; Sulahian, A | 1 |
| Fretzayas, A; Karpathios, T; Kitsiou, S; Mathioudakis, J; Moustaki, M | 1 |
2 other study(ies) available for meglumine antimoniate and Splenic Diseases
| Article | Year |
|---|---|
Therapeutic effect of reference antileishmanial agents in murine visceral leishmaniasis due to Leishmania infantum.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Female; Leishmania infantum; Leishmaniasis, Visceral; Liver Diseases, Parasitic; Lung Diseases, Parasitic; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Parasitology; Paromomycin; Splenic Diseases | 1996 |
Splenic granulomatous lesions in immunocompetent pediatric patients with visceral leishmaniasis.
Topics: Antiprotozoal Agents; Child; Child, Preschool; Granuloma; Humans; Immunocompetence; Infant; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Prognosis; Splenic Diseases; Treatment Outcome | 2001 |